论文部分内容阅读
目的通过观察伊马替尼治疗慢性粒细胞白血病过程中出现罕见毒副反应,探讨甲磺酸伊马替尼在治疗慢性粒细胞白血病中的安全性。方法对1例伊马替尼治疗晚期慢性粒细胞白血病加速期的过程中出现罕见毒副反应的临床资料进行分析,并结合文献复习。结果1例确诊为慢性粒细胞白血病的患者接受甲磺酸伊马替尼治疗后,出现尿崩症、窦性心动过速伴肌肉损坏,停药70多天再次减量服用后又出现类似症状。结论伊马替尼治疗慢性粒细胞白血病加速期可能出现罕见的严重不良反应。
Objective To observe the rare toxicity of imatinib in the treatment of chronic myeloid leukemia and to explore the safety of imatinib mesylate in the treatment of chronic myeloid leukemia. Methods One case of imatinib in the treatment of advanced CML patients during the accelerated phase of the clinical data were analyzed, combined with the literature review. Results One patient with chronic myeloid leukemia who received imatinib mesylate had diabetes insipidus and sinus tachycardia with muscle damage. Similar symptoms occurred after more than 70 days of withdrawal . Conclusion Imatinib treatment of chronic myeloid leukemia may occur during the accelerated rare serious adverse reactions.